-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Taiwan-Based Jyong Biotech Announces Nasdaq Listing With $20M Initial Public Offering Of 2,666,667 Ordinary Shares At 7.50 Per Share

Benzinga·06/17/2025 06:04:32
Listen to the news

The net proceeds from the Offering will be used for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%).